Scholarlink

Background <p>Long non-coding RNAs (lncRNA) H19 has drawn special attention because of its varied role in several malignancies, including OSCC. Therefore, this study was conducted to assess the association between H19-miR675-p53 by in-silico analysis, quantify the expression levels of H19, miRNA-675, and target oncogene p53 in cancerous versus normal individuals, and Correlate the Clinicopathological findings with their expression pattern.</p> Methods <p>The secondary structure of lncRNA H19 was predicted using the RNAfold web server (<a href="http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi">http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi</a>). The FASTA sequence of H19 was retrieved from the NCBI database (<a href="https://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</a>). We performed molecular docking studies to analyze the interaction between miRNA-675 and p53 using the MDockPP (<a href="https://zougrouptoolkit.missouri.edu/MDockPP/">https://zougrouptoolkit.missouri.edu/MDockPP/</a>) web server. Real-time PCR was used to measure the amounts of H19 and miR-675, and Immunohistochemistry was used to analyse the pattern of p53 expression.</p> Result <p>The study successfully associated miR-675 from the first exon of H19 modulating p53 via in silico analysis. It was found that H19 and miR-675 levels were higher in OSCC patients (3.12 ± 1.16) compared to healthy patients (1.0 ± 0.0), and was statistically significant (<i>p</i>-value &lt; 0.001).</p> Conclusion <p>The specificity of H19 expression in OSCC compared to normal presents an attractive target for cancer-specific therapies, minimizing the risk of off-target effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated in-silico and in-vitro analysis of lncRNA H19/miRNA-675/p53 in OSCC: Structural characterization and molecular docking insights

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Ramya Sekar,
  • Selvaraj Jayaraman,
  • Vishnupriya Veeraraghavan,
  • Saranya Varadarajan,
  • Manikandan Alagumuthu,
  • Peramaiyan Rajendran,
  • Bargavi Venkatesalu

摘要

Background

Long non-coding RNAs (lncRNA) H19 has drawn special attention because of its varied role in several malignancies, including OSCC. Therefore, this study was conducted to assess the association between H19-miR675-p53 by in-silico analysis, quantify the expression levels of H19, miRNA-675, and target oncogene p53 in cancerous versus normal individuals, and Correlate the Clinicopathological findings with their expression pattern.

Methods

The secondary structure of lncRNA H19 was predicted using the RNAfold web server (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). The FASTA sequence of H19 was retrieved from the NCBI database (https://www.ncbi.nlm.nih.gov/). We performed molecular docking studies to analyze the interaction between miRNA-675 and p53 using the MDockPP (https://zougrouptoolkit.missouri.edu/MDockPP/) web server. Real-time PCR was used to measure the amounts of H19 and miR-675, and Immunohistochemistry was used to analyse the pattern of p53 expression.

Result

The study successfully associated miR-675 from the first exon of H19 modulating p53 via in silico analysis. It was found that H19 and miR-675 levels were higher in OSCC patients (3.12 ± 1.16) compared to healthy patients (1.0 ± 0.0), and was statistically significant (p-value < 0.001).

Conclusion

The specificity of H19 expression in OSCC compared to normal presents an attractive target for cancer-specific therapies, minimizing the risk of off-target effects.